Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL | Leukemia
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results | Blood Cancer Journal
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial | Haematologica
Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia | Annals of Hematology
Cancers | Free Full-Text | Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial - ScienceDirect
The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: a multicentre, non-randomised, open-label phase 2 study - eClinicalMedicine
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Jennifer A. Woyach: Results of Alliance North American Intergroup Study A041202 - YouTube
ALLIANCE A041202 - Study Design | IMBRUVICA® (ibrutinib) HCP
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study | Leukemia
Ibrutinib in the treatment of chronic lymphocytic leukemia: 5 years on - Molica - 2020 - Hematological Oncology - Wiley Online Library
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial - The Lancet Oncology
A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia | Trials | Full Text
RESONATE-2 - Study Design | IMBRUVICA® (ibrutinib) HCP
Ibrutinib + Venetoclax in CLL - Slideset Download - Hematology 2018 | CCO
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia | NEJM
Cancers | Free Full-Text | First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL | NEJM
Treatment Initiation and Selection in Newly Diagnosed CLL - ppt download
Ibrutinib and Rituximab (IR) is Superior to Chemo-immunotherapy (CIT) in CLL: Big News, or is it really? And did they get it right? - CLL Society
